ASMB

Assembly Biosciences

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/14/26

Business Summary

AGX operates in Engineering & Construction, generating cash by designing and executing large-scale industrial projects where execution speed, technical precision, and cost discipline drive profitability. The company converts engineering expertise into high-margin contracts, evidenced by its 29.80% operating margin and strong ROIC. Its moat likely stems from project management capability, reputation, and the ability to consistently deliver complex builds without cost overruns. In this business, credibility and capital discipline create repeat opportunities, and high returns on invested capital suggest AGX has built a system that extracts substantial cash from each dollar deployed.

VALUATION

P/E

-

Market Cap ($M USD)

$450

Forward P/E

-

PEG

-

PRICE TO SALES

4.4

PRICE TO BOOK

2.2

EV / EBITDA

-17.1

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.55

Next Year EPS Growth Estimate

-$2.31

Next Year Revenue Growth Estimate

-31.70%

Return on Equity (ROE)

-3.00%

Operating Margin

-16.80%

Debt-to-Equity

0

Piotroski F-Score

3

Altman Z-Score

1.9

Return on Invested Capital (ROIC)

-9.90%%

Current Ratio

5.2

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 62.1x trailing earnings and 40.5x forward earnings, the market is clearly pricing AGX as a premium compounder, not a cyclical contractor. A PEG of 1.6 suggests growth is not cheap, but it is not egregiously priced if execution holds. The Altman Z-Score of 9.1 signals extremely low bankruptcy risk, reinforced by a modest 14.30% Debt/Equity ratio and a healthy 1.6 current ratio. This is not a distressed value play; it is a high-quality industrial trading at a growth multiple, and the valuation only works if its 33.60% ROIC and 29.80% operating margin prove durable. The market is not mispricing distress—it is betting aggressively on continued capital efficiency.

AI Exposure / Tech Reliance

As an Engineering & Construction company within Industrials, AGX operates in a sector increasingly influenced by automation, digital project modeling, and AI-driven efficiency tools. Firms that integrate AI into project design, cost estimation, and scheduling can materially expand margins and reduce execution risk. With a 29.80% operating margin, AGX appears positioned to benefit from operational leverage if it continues adopting advanced engineering technologies.

The Bull Case

A GARP investor buys this because 33.60% ROIC in an Industrials name is elite, especially paired with 20.90% ROE and nearly 30% operating margins—this is not a commoditized contractor profile. The Piotroski F-Score of 6 indicates solid, though not perfect, financial health and operational stability. Low leverage at 14.30% Debt/Equity combined with an Altman Z-Score of 9.1 provides balance sheet safety that most engineering peers lack. Even at 40.5x forward earnings, the premium can be justified if capital continues compounding at current returns, especially with institutional ownership at $452.17 suggesting strong professional sponsorship. This is a quality compounder masquerading inside a cyclical industry.

The Bear Case

The valuation is the obvious problem: 62.1x P/E and 9x sales leave zero margin for error in a traditionally cyclical sector. A PEG of 1.6 is not cheap, and with 14.90% of float sold short, the market is clearly questioning the durability of earnings. Price/Book at 18.2 is extreme for Engineering & Construction, implying the market is capitalizing returns far into the future. Any slowdown—despite projected sales growth of $14.92 next year—would compress multiples violently. This is a high-expectation stock in a low-forgiveness industry.

Market Sentiment & Smart Money

Short Interest %

11.20%

Analyst Consensus

1.33

Average Analyst Price Target

$46.60

Institutional Ownership %

60.10%

1-Year Beta

1.6

Insider Buying % (6 Mo)

32.20%%

Distance to 52-Week High

71.60%%

Distance to 52-Week Low

348.70%%